Form 483

Dhaliwal Labs South LLC Form 483, 2025-06-26

FDA issued a Form 483 to Dhaliwal Labs South LLC on 2025-06-26 with 3 public-safe observations.

483· Form 483 issuedHuman Drugs3 observations

Dhaliwal Labs South LLC · Dallas, United States · Issued June 26, 2025

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

26 Jun 2025
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Margaret M Annes, Kevin T Nguyen

26 Jun 2025
21 CFR 211.182

Written records kept in individual logs

Cited by Margaret M Annes, Kevin T Nguyen

26 Jun 2025
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Margaret M Annes, Kevin T Nguyen

Inspected site

DLDhaliwal Labs South LLCDallas, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.182Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 3 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere